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Heart failure affects millions of patients worldwide and 
the impact on the health care systems is expected to 
increase as the population grows older. Approximately 
half of elderly patients with heart failure have preserved 
ejection fraction [1]. Heart failure with preserved 
ejection fraction is a heterogenous and poorly under-
stood entity, spanning a broad spectrum of etiologies, of 
which cardiac amyloidosis is becoming increasingly 
recognized. Nonetheless, studies suggest that cardiac 
amyloidosis is markedly underdiagnosed: 
- Autopsy studies of octogenarians have shown a 25% 
prevalence of myocardial transthyretin deposition [2].  
- In a study of patients aged 60 years or older admitted 
for heart failure with preserved ejection fraction, and 
with left ventricular hypertrophy, a diagnosis of trans-
thyretin cardiac amyloidosis was made in 13% after 
screening for the disease using scintigraphy [3].   
- Studies on patients with severe aortic stenosis have 
shown a prevalence of cardiac amyloidosis in 6% of 
patients undergoing surgical valve replacement, and 
16% of patients undergoing transcatheter valve 
replacement [4, 5], diagnosed by myocardial biopsy and 
scintigraphy respectively. 
The underdiagnosing of cardiac amyloidosis is 
presumably due to the subtle clinical presentation in a 
population already burdened with comorbidities, and 
possibly due to the belief that diagnosis will not affect 
the outcomes, as no specific treatment has been 
available. Indeed, the prognosis in patients with cardiac 
amyloidosis is poor, but novel and specific 
pharmacological agents have recently been approved 
and shown to be effective [6, 7], warranting the quest 
for earlier diagnosis of cardiac amyloidosis.  
Due to the unaggressive diagnostic approach, the true 
epidemiology of cardiac amyloidosis is unknown. In 
clinical practice, certain signs are known to be found 
often in patients with cardiac amyloidosis, such as 
carpal tunnel syndrome and biceps tendon rupture. 
However, this has only been studied in small and highly 
selected patient series and the reverse – how often 
patients with carpal tunnel syndrome or biceps tendon 
rupture have or develop cardiac amyloidosis - has not 
been evaluated previously. Hence, it was unknown 
whether carpal tunnel syndrome is an independent risk 
marker of future cardiac amyloidosis. Clarifying this 
could prove valuable in early detection of the disease.  
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In a recent study, we utilized the Danish national 
registries to investigate the associations between 
previous surgery for carpal tunnel syndrome, cardiac 
amyloidosis, and adverse cardiovascular outcomes [8]. 
Comparing 56,032 patients treated surgically for carpal 
tunnel syndrome in the period 1996-2012, with age and 
gender matched controls from the general population, 
we found that carpal tunnel syndrome was associated 
with a 12-fold higher risk of diagnosed cardiac amyloi-
dosis compared to control subjects, but the absolute 
incidence risk of incident cardiac amyloidosis was low. 
Carpal tunnel syndrome was also associated with a 
significantly increased risk of other adverse cardio-
vascular events such as heart failure, atrial fibrillation, 
atrioventricular block and pacemaker/ICD implantation. 
Being an observational study the assessment of 
causality is limited. Nonetheless, our results suggest 
that carpal tunnel syndrome may be an early marker for 
risk of developing cardiac amyloidosis and adverse 
cardiovascular events, and thereby provide an 
opportunity for early disease detection. Given the low 
absolute risk of developing (diagnosed) cardiac 
amyloidosis more studies are needed to determine 
which patients with carpal tunnel syndrome should 
undergo further testing. As the diagnosis often can be 
made safely and non-invasively using a combination of 
biochemistry, echocardiography and scintigraphy, the 
threshold for investigating appropriate patients might be 
lowered allowing for screening of individuals at risk. 
Previously considered a rare disease of limited clinical 
interest with no treatment available, increasing evidence 
is pointing towards cardiac amyloidosis being a more 
common condition for which effective treatment is 
emerging. As treatment for cardiac amyloidosis appears 
to be more effective if initiated before manifest heart 
failure (at which time the patient is normally referred to 
cardiac evaluation), improved insight in the true 
epidemiology of cardiac amyloidosis is crucial to enable 
early identification of patients suitable for screening.  
Although it will need refining, our study suggests one 
potential pathway for early disease detection and 
consequently better treatment of cardiac amyloidosis. 
Future studies will determine the clinical characteristics 
which should mandate work-up for cardiac amyloidosis. 
This, together with more information on optimal use of 
the new disease modifying drugs, will finally improve 
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the quality of life and survival of patients with cardiac 
amyloidosis.  
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